Дина Бен-Иехуда

Научные публикации

• Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
• Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
• Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
• From skepticism to openness: a qualitative narrative analysis of medical students' attitudes following an integrative medicine course
• From the "what" to the "how": Teaching integrative medicine-related skills to medical students during COVID-19
• Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
• Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
• Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
• Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma
• Parameters associated with sperm quality prior to chemotherapy in lymphoma patients
• Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
• THE TIME HAS COME! COMPLEMENTARY MEDICINE IN MEDICAL TRAINING IN ISRAEL
• Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients
• Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
• Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
• Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
• Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
• Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
• Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
• American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City
• Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
• Serum organochlorines and non-Hodgkin lymphoma: A case-control study in Israeli Jews and Palestinians
• The oncogenic fusion protein CBFB-SMMHC downregulates CD48 to evade NK cell recognition
• A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
• Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
• Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma
• Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
• Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
• Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients
• Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
• Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians
• The JAK2V617F mutation in normal individuals takes place in differentiating cells
• The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma
• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
• Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
• Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions
• Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
• Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
• Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and immune response to hepatitis B
• Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
• Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
• A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
• Autologous transplantation and maintenance therapy in multiple myeloma
• A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
• Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma
• tLivin displays flexibility by promoting alternative cell death mechanisms
• Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia